ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login


Journal: International Journal of Advanced Research (Vol.10, No. 02)

Publication Date:

Authors : ; ;

Page : 640-645

Keywords : Centchroman Mastalgia Fibroadenoma AndFibroadenosis;

Source : Downloadexternal Find it from : Google Scholarexternal


Background:Mastalgia and fibrocystic disease of breast (fibroadenosis and fibroadenomaare common among the women in reproductive age group.Mostof the drugs used for these conditions are expensive and have side effects.Centchroman is a novel ono-steroidal antiestrogen,becouse of its selective antiestrogenic action cantchroman used for the treatment of mastagia and fibroadenoma.Centchroman therapy in FA treatment showed statistically significant regression of volume.and regression of pain. AimsandObjectives:-The purpose of this study is to study the effectiveness of centchroman on mastalgias and fibroadenomasStudy design:Randomized control trial Material: 60 Patients Study and follow-up period 1 Year Materials and mathods:Patients attending general surgery op with complaints of breast lump less than35 yrs of age will be taken detailed clinical history, clinical examination, ultrasonagram (USG) of both breast and fine needle aspiration (FNAC)/ core needle biopsy Patients who are all diagnosed as fibroadenoma (FA) and willing for simple observation with reassurance at least for 6 months will be included in this study after getting informed consent randomization included in study group and control group. Patients in study group will get Centchroman 30mg orally on alternative days and for control group patients only observation with simple assurance. Study group patients will be reviewed after 1week to check tolerance and later follow-up at 4, 12, and 24 weeks. USG will be done at 0 days, 4, 12 and 24 weeks for both groups to assess regression Results:The study showed statistical difference in fibroadenoma patients with significant reduction in their sizes in patients treated with centchroman even at 4th week. Further the difference between study and control group became statistically highly significant at 12th and 24thweek.The study did not show any statistical difference in mastalgia patients treated with centchroman at 4th and 8th week. But the difference between study and control group became statistically significant at 12th and 24th week with greater reduction in pain. Conclusions:Centchroman therapy in FA treatment showed statistically significant regression of volume.Centchroman therapy inmastalgias treatment showed statistically significant regression of pain,Long term results beyond 6 months needs further study.It is useful in patient who is willing for observation instead of enucleation of FA .Patients more than 35 yrs old and young patients (<35 yrs) with suspicious histology, recurrence, family h/o carcinoma breast, anxiousness and no response to conservative management are the ideal candidate for active management as excisional biopsy ( enucleation of FA).

Last modified: 2022-03-10 16:07:18